GlassScriptPhysician profile
Irfan Bhatti
NPI 1174780167
$421.72
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $18.20 · 2021: $91.45 · 2022: $177.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $131.34 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $93.37 | 2019 | |
| Corium, LLC | $40.95 | 2022 | |
| Neurocrine Biosciences, INC. | $39.41 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.09 | 2022 | |
| Shire North American Group INC | $30.92 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.29 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.20 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.15 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irfan Bhatti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.